Compare VTSI & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VTSI | ATNM |
|---|---|---|
| Founded | 1993 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Miscellaneous manufacturing industries | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.9M | 50.2M |
| IPO Year | N/A | N/A |
| Metric | VTSI | ATNM |
|---|---|---|
| Price | $4.88 | $1.55 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $7.00 | $4.00 |
| AVG Volume (30 Days) | 56.0K | ★ 203.9K |
| Earning Date | 11-10-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $24,934,267.00 | $90,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $13.39 | $42,943.57 |
| P/E Ratio | $341.38 | ★ N/A |
| Revenue Growth | N/A | ★ 11.11 |
| 52 Week Low | $3.57 | $1.03 |
| 52 Week High | $7.49 | $2.41 |
| Indicator | VTSI | ATNM |
|---|---|---|
| Relative Strength Index (RSI) | 44.34 | 60.20 |
| Support Level | $4.81 | $1.37 |
| Resistance Level | $5.13 | $1.54 |
| Average True Range (ATR) | 0.13 | 0.08 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 44.09 | 86.27 |
VirTra Inc is a U.S.-based company that is engaged in the sale and development of the judgmental use of force training simulators and firearms training simulators for law enforcement, military, and commercial uses. It sells simulators and related products across the globe through a direct sales force and international distribution partners. The services provided by the company include installation, training, limited warranties, service agreements, and related support. The company sells and supports the use of force training and marksmanship firearms training systems and accessories for law enforcement, military, or civilian use. Company's The product lany includes simulators, upgrade components, scenarios, scenario software, recoil kits, Threat Fire, and other accessories.
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.